# US 2017/0253592 A1 · N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253592 A1
- Document ID: US20170253592A1
- Status: Published application
- Kind: A1
- Application number: 15/511,515
- Filed: 2015-09-14
- Published: 2017-09-07
- Earliest claimed: 2014-09-16
- Assignees: Chronos Therapeutics Limited
- Applicants: Chronos Therapeutics Limited
- Inventors: Susanna CREMONESI; Fabrizio MICHELI; Teresa SEMERARO; Luca TARSI; Tim LUKER; Colin LESLIE
- Web page: https://patentgrep.com/patent/US20170253592A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/30: for treating abuse or dependence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/48: having an acyclic carbon atom attached in position 4
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.

## Claims

### Claim 1

A compound according to formula I,
wherein:
A is selected from phenyl and heteroaryl;
B is selected from phenyl and heteroaryl;
L is a linker selected from alkylene and O;
R1 is selected from H, alkyl, alkoxy, S-alkyl, S(O)qalkyl, COR5, CONR5R6, COOR5, CH2OH, OH, F and Cl;
R2 is selected from NR7R8, CR11R12NR7R8, CONR7R8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8, wherein R1 is alkyl, alkoxy, CH2OH, COR5, CONR5R6 or COOR5 when R2 is NR7R8;
R3 is selected from H, alkyl, alkoxy, NR7R8, CH2OH, OH, F and Cl;
or R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, wherein the heterocyclyl or heteroaryl contains at least one ring member selected from N and NR13; provided that when R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, L is O;
provided that when R1 is H, either
R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl; or
R3 is selected from alkyl, alkoxy, NR7R8, CH2OH, OH, F and Cl;
R4, R5 and R6 are each independently selected from H and alkyl;
R7 and R8 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, and C(O)R10, wherein when R7 is C(O)R10, R8 is H or alkyl; or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl;
R9a, R9b, R9c, R9d, R9e and R9f are independently selected from H and alkyl;
R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl;
is absent or represents a bond, wherein when is a bond R1 and R4 are absent;
m is 0, 1 or 2, wherein when m is 2, n is 0;
n is 0, 1 or 2, wherein when n is 2, m is 0;
q is 1 or 2;
alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, cycloalkyl, heterocyclyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14;
cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms (C3-C7); cycloalkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, and NR13R14;
phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
alkylene is a bivalent C1-3 straight-chained alkyl radical or a bivalent C3-4 branched alkyl radical, wherein alkylene may optionally be substituted with 1 or 2 substituents selected from S-alkyl, S(O)alkyl, S(O)2alkyl, heterocyclyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14;
heterocyclyl is a monocyclic ring which is saturated or partially unsaturated, containing, where possible, 1 or 2 ring members independently selected from N, S, O and NR13 and 2 to 5 carbon atoms; heterocyclyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, oxo, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
heteroaryl is a 5 or 6 membered aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR13, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR4 and NR13R14;
R11, R12, R13 and R14 are independently selected from H and alkyl;
and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof;
wherein the compound of formula I is not:

### Claim 2 (depends on 1)

The compound of claim 1 wherein when R2 and R3 come together with the carbon atoms to which they are attached to form heterocyclyl or heteroaryl, the sum of m and n is 2.

### Claim 3 (depends on 1)

The compound of claim 1 wherein:
R1 is selected from alkyl, alkoxy, S-alkyl, S(O)qalkyl, COR5, CONR5R6, COOR5, CH2OH, OH, F and Cl;
R2 is selected from NR7R8, CONR7R8, CR11R12NR7R8, (CR11R12)2NR7R8 and (CR11R12)3NR7R8;
R3 is selected from H and alkyl;
R4, R5 and R6 are each independently selected from H and alkyl;
is absent.

### Claim 4 (depends on 1)

The compound of claim 1 wherein n is 1 and m is 0 or 1.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R9a, R9b, R9c, R9d, R9e, R9f, R11 and R12 are all H.

### Claim 6 (depends on 1)

The compound of claim 1, according to formula IA,
wherein:
A is selected from phenyl and heteroaryl;
B is selected from phenyl and heteroaryl;
L is a linker selected from alkylene and O;
R1 is selected from CH2OH, OH, F and Cl;
R7 and R8 are independently selected from H, alkyl, cycloalkyl, heterocyclyl, and C(O)R10, wherein when R7 is C(O)R10, R8 is H or alkyl; or R7 and R8 may come together with the nitrogen atom to which they are attached to form heterocyclyl;
R10 is selected from alkyl, aryl, heterocyclyl and heteroaryl;
m is 0 or 1;
alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents selected from cycloalkyl, heterocyclyl, S-alkyl, S(O)alkyl, S(O)2alkyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14;
cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms (C3-C7); cycloalkyl may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, alkoxy, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14;
phenyl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
heterocyclyl is a monocyclic ring which is saturated or partially unsaturated, containing, where possible, 1 or 2 ring members independently selected from N, S, O and NH and 2 to 5 carbon atoms; heterocyclyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, oxo, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
heteroaryl is a 5 or 6 membered aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR13, S and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14;
alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1, 2, 3, 4 or 5 substituents independently selected from S-alkyl, S(O)alkyl, S(O)2alkyl, alkyl, OH, —CN, CF3, COOR13, CONR13R14, F, Cl, NR13COR14 and NR13R14;
R13 and R14 are independently selected from H and alkyl;
and tautomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), pharmaceutically acceptable salts and solvates thereof.

### Claim 7 (depends on 6)

The compound of claim 6 wherein m is 1.

### Claim 8 (depends on 1)

The compound of claim 1 wherein R1 is OH.

### Claim 9 (depends on 1)

The compound of claim 1 wherein L is O.

### Claim 10 (depends on 1)

The compound of claim 1 wherein A is phenyl, pyridyl or pyrimidinyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14.

### Claim 11 (depends on 1)

The compound of claim 1 wherein A is phenyl, 2-pyridyl or 1,3-pyrimidinyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, F, Cl, —CN and CF3.

### Claim 12 (depends on 1)

The compound of claim 1 wherein A is selected from the group consisting of:

### Claim 13 (depends on 1)

The compound of claim 1 wherein B is phenyl, optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, cycloalkyl, heterocyclyl, alkoxy, S-alkyl, S(O)alkyl, S(O)2alkyl, OH, F, Cl, —CN, OCF3, CF3, NR13COR14 and NR13R14.

### Claim 14 (depends on 1)

The compound of claim 1 wherein B is selected from the group consisting of:

### Claim 15 (depends on 1)

A compound of claim 1 selected from:
4-[(dimethylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol;
4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
4-{[cyclopropyl(methyl)amino]methyl}-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-[(methylamino)methyl]piperidin-4-ol;
4-[(3,3-difluoropyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
4-[(2, 5-dimethylpyrrolidin-1-yl)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
4-[(tert-butylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
1-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrrolidin-2-one;
4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
{4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanamine;
4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-(2-fluoro-3-phenoxyphenyl)piperidin-4-ol;
4-(aminomethyl)-1-[2-fluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol;
{4-amino-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanol;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-methylpropanamide;
2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-(propan-2-yloxy)acetamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)azetidine-3-carboxamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)benzamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1H-pyrazole-4-carboxamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrazine-2-carboxamide;
2-amino-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide;
3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
(3 S)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
(3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)-2-methylpropanamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)azetidine-3-carboxamide;
4-(3-fluorophenoxy)-2-{3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-6-(trifluoromethyl)pyrimidine;
6-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-decahydro-1,6-naphthyridine;
and pharmaceutically acceptable salts and solvates thereof.

### Claim 16 (depends on 15)

A compound of claim 15 selected from:
4-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-[(methylamino)methyl]piperidin-4-ol;
4-(1,4-diazepan-1-ylmethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
4-[(tert-butylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
4-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-ol;
{4-fluoro-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanamine;
4-(aminomethyl)-1-[3-fluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-[2,5-difluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-(2-fluoro-3-phenoxyphenyl)piperidin-4-ol;
4-(aminomethyl)-1-[2-fluoro-3-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-[2,3-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol;
4-(aminomethyl)-1-[3,4-difluoro-5-(3-fluorophenoxy)phenyl]piperidin-4-ol;
{4-amino-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl}methanol;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-methylpropanamide;
2-cyclopropyl-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-2-(propan-2-yloxy)acetamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)azetidine-3-carboxamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)benzamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)-1H-pyrazole-4-carboxamide;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)pyrazine-2-carboxamide;
2-amino-N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-4-hydroxypiperidin-4-yl}methyl)acetamide;
3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
(3S)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
(3R)-3-[(cyclopropylamino)methyl]-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
3-(aminomethyl)-1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]pyrrolidin-3-ol;
N-({1-[4-(3-fluorophenoxy)-6-(trifluoromethyl)pyrimidin-2-yl]-3-hydroxypyrrolidin-3-yl}methyl)azetidine-3-carboxamide;
4-(3-fluorophenoxy)-2-{3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl}-6-(trifluoromethyl)pyrimidine;
and pharmaceutically acceptable salts and solvates thereof.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method of treating or preventing a condition, disease or disorder ameliorated by inhibition of a dopamine transporter, the method comprising administering the compound of claim 1 to a subject in need thereof.

### Claim 20 (depends on 19)

The method of claim 19 wherein said condition, disease or disorder is selected from sexual dysfunction, affective disorders, anxiety, depression, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, chronic fatigue and impulse control disorder.

### Claim 21 (depends on 19)

The method of claim 19 wherein said condition, disease or disorder is selected from attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) or binge-eating.
